Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Rating) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,225 shares of the company’s stock, valued at approximately $47,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Amalgamated Bank acquired a new position in Rhythm Pharmaceuticals in the 1st quarter worth approximately $61,000. Arizona State Retirement System acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter worth approximately $42,000. Mirabella Financial Services LLP acquired a new position in Rhythm Pharmaceuticals in the 1st quarter worth approximately $121,000. Chicago Partners Investment Group LLC acquired a new position in Rhythm Pharmaceuticals in the 1st quarter worth approximately $39,000. Finally, Jane Street Group LLC acquired a new position in Rhythm Pharmaceuticals in the 1st quarter worth approximately $218,000. 90.60% of the stock is owned by hedge funds and other institutional investors.
Rhythm Pharmaceuticals Stock Performance
Rhythm Pharmaceuticals stock opened at $26.34 on Monday. The company’s fifty day moving average price is $24.01 and its 200 day moving average price is $14.97. Rhythm Pharmaceuticals, Inc. has a 1 year low of $3.04 and a 1 year high of $30.98. The stock has a market capitalization of $1.48 billion, a P/E ratio of -7.36 and a beta of 1.98.
Analyst Ratings Changes
Insider Activity at Rhythm Pharmaceuticals
In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 13,493 shares of the firm’s stock in a transaction on Friday, August 19th. The stock was sold at an average price of $24.83, for a total value of $335,031.19. Following the transaction, the insider now owns 2,224 shares in the company, valued at approximately $55,221.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is owned by corporate insiders.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
- Get a free copy of the StockNews.com research report on Rhythm Pharmaceuticals (RYTM)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.